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differences became apparent regarding issues such as pri-
vacy, which was of greater concern to Italian patients than
US patients, and bureaucratic issues surrounding drug
availability, which were difficult for some US patients but
not for Italian patients. Finally, in response to patient sug-
gestions, the questionnaire includes positive wording
about “taking” rather than “missing” medication. 
CONCLUSION: In this small group of patients, the
PMAQ7 was judged to be relevant for patients, offering a
promising initial indication of the validity of the instru-
ment to monitor and manage adherence to antiretroviral
therapy.
PID6
HEALTH-RELATED QUALITY OF LIFE CHANGES 
IN PATIENTS WITH ONYCHOMYCOSIS
Lubeck DP1, Doyle JJ2, Schein JR2, Potter LP3, Prebil LA3
1University of California/San Francisco, San Francisco, CA, 
USA; 2Novartis Pharmaceuticals Corporation, East Hanover, 
NJ, USA; 3Lewin-TAG, San Francisco, CA, USA
OBJECTIVES: The objective of the study was to examine
changes in health-related quality of life (HRQoL) in an
observational database of patients with onychomycosis
receiving various treatments by either dermatologists or
podiatrists. 
METHODS: Dermatologists or podiatrists at eight US
sites reported on clinical outcomes at baseline and follow-
up (4 and 9 months). Patients completed a validated
HRQoL questionnaire at the same time points that mea-
sured the impact of onychomycosis on generic (general
health perception, pain, mental health, social functioning,
health distress, physical functioning, and health transition)
and disease-specific items (toe symptom frequency, toe
symptom bother, problems with appearance, problems
with activities, stigma, and satisfaction with treatment). 
RESULTS: For this study 113 patients completed the
questionnaire at baseline and follow-up. Forty-eight per-
cent of patients were treated by dermatologists, 52% by
podiatrists. Patients were predominately male (58%). At
month 9, patients treated with oral antifungal therapy had
significant improvements in physical functioning, toenail
symptoms, toenail bother, problems with appearance and
activities, stigma, pain and satisfaction with treatment
(p  0.01) when compared with patients treated with non-
oral therapy. 
CONCLUSION: The data indicate that patients with on-
ychomycosis who seek treatment with oral therapy re-
port significant improvement in HRQoL and satisfaction
compared with patients treated with non-oral therapy.
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OBJECTIVE: The purpose of this study was to evaluate
cost per mycological treatment of oral antifungal drugs
and to determine the most cost-effective primary treatment
for onychomycosis using the Idaho Medicaid claims data. 
METHOD: Oral griseofulvin, itraconazole, ketoconazole,
fluconazole, and terbinafine were the antifungal drugs used
to determine the cost per mycological treatment and relative
cost-effectiveness ratios. The Idaho Medicaid database was
screened using ICD-9 code, from October 1992 to Novem-
ber 1998 to identify patients receiving treatment for ony-
chomycosis. Five hundred and forty-nine patients using one
antifungal drug were identified and were followed for a pe-
riod of 1 year following a diagnosis of fungal infection of
the nail and an associated prescription of an antifungal
agent. Costs for drugs, physician visits, and drug manage-
ment was used in the treatment model. CPT codes were
used to identify laboratory cost involved in drug manage-
ment. The Mycological cure rates obtained from clinical tri-
als reported in literature were used as a measure of treat-
ment efficacy. Relative cost-effectiveness was calculated
assigning a value of 1.0 to terbinafine. 
RESULTS: The mean total treatment cost for each pa-
tient for griseofulvin was $460.72, for itraconazole was
$872.91, for ketoconazole was $464.78, for fluconazole
was $216.80, and that of terbinafine was $186.57. Ter-
binafine also had the lowest cost ($230.33) per mycolog-
ical treatment after adjusting for cure rates, for one treat-
ment regimen. Relative cost-effectiveness for griseofulvin
was 2.94, for itraconazole 4.07, for ketoconazole 3.36,
and fluconazole was 1.58. 
CONCLUSIONS: Terbinafine was found to be a more
cost-effective primary drug compared to griseofulvin,
itraconazole and ketoconazole in the treatment of ony-
chomycosis. Fluconazole was found to be the second
most cost-effective next to terbinafine.
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OBJECTIVE: A retrospective analysis to compare cost,
days of therapy, and demographic data for patients on
antifungal therapies for nail involvement in a Medicaid
population. 
METHOD: Diagnosis codes combined with antifungal
medications were used to identify patients on different
therapies for onychomycosis. Griseofulvin, itraconazole,
ketoconazole, fluconazole, and terbinafine were the oral
antifungal drugs compared. Drug costs and physician costs
were analyzed. The total number of different medications,
other than those for onychomycosis, was used as a mea-
sure of health. Demographic variables of age and gender
were evaluated. 
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RESULTS: Five hundred and ninety eight patients (68.9%
females and 31.3% males) with a mean age of 50 years
were identified. There was a significant difference (p 
0.01) in the age of patients on different medications. Pa-
tients on fluconazole were significantly older compared to
other therapies (p  0.01). The total treatment cost of flu-
conazole was found to be significantly less expensive than
terbinafine, itraconazole and griseofulvin (p  0.01). Sig-
nificant differences in cost prevailed after using analysis of
covariance to remove the bias of age and gender between
the different therapies. It was also found that fluconazole
was more frequently prescribed to patients with poor
health, as identified by total number of different drugs.
The duration of therapy for griseofulvin was significantly
greater (p  0.01) than all other drugs. Forty-two percent
of all therapies were for 30 days or less. Fifty percent re-
ceived therapy for less than 45 days. Only 12% received
therapy for over 120 days. 
CONCLUSION: Age, duration, and costs of therapy are
related to the choice of drug. Additionally, 42% were not
on therapy long enough to have a therapeutic benefit.
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OBJECTIVE: Amphotericin B lipid complex (ABLC) has
been shown to have renal-sparing effects compared to
conventional amphotericin B (AmB). It is unknown,
however, if continued use of ABLC confers any benefit
once a patient requires hemodialysis. The purpose of this
pilot study was to evaluate the outcomes of patients on
hemodialysis who received ABLC. 
METHODS: Patients who received ABLC after initiating
hemodialysis were identified. Variables collected and as-
sessed included patient demographics and clinical character-
istics, indication for ABLC, patient outcomes, and charges. 
RESULTS: A total of 21 patients met our criteria. Over-
all, the mean age was 49 years, and 13 (62%) were male.
Eleven patients had a history of solid organ transplanta-
tion, four had bone marrow transplants, and six had
other medical conditions. The majority of patients had
fungal pathogens identified: six Candida sp., five As-
pergillus sp., four Torulopsis sp. Only seven (33%) pa-
tients were treated with AmB prior to hemodialysis, re-
ceiving a mean eight doses per patient. Eleven patients
were treated with ABLC prior to receiving hemodialysis.
A total of 244 doses of ABLC at a cost of $67,064 were
administered in these 21 patients while concurrently re-
ceiving hemodialysis. Thirteen (62%) of patients died
during that admission while an additional three patients
were dialysis dependent at discharge. Five (24%) patients
were discharged from the hospital off dialysis. Of the five
patients whose renal function recovered, one continued
to receive outpatient antifungal therapy. 
CONCLUSIONS: The majority (76%) of severely ill pa-
tients on hemodialysis receiving ABLC will either die or
remain on dialysis at discharge. A retrospective cohort
study of ABLC versus AmB is planned to determine if
ABLC is cost-effective in patients on hemodialysis.
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SM, a complicated and variable medical decision process,
accounts for a large number of hospitalizations, proce-
dures, and prescriptions. 
OBJECTIVES: The purpose was to develop and validate
a DAF representing current clinical management prac-
tices and outcomes for SM. 
METHODS: An expert panel (EP) comprised of seven
physicians (four pediatric/infectious disease specialists, one
neurologist, one family practitioner, and one emergency
medicine physician) developed and validated the DAF. The
Integrative Group Process (IGP), a modified Delphi tech-
nique, was used with the EP. Seed algorithms based on lit-
erature review were provided to facilitate the discussion.
In a step-by-step process, each panelist confirmed struc-
tural validity and then estimated probability ranges anony-
mously. After the first probability ranges had been identi-
fied, the baselines were determined and complementary
branches were computed and confirmed. Consensus on the
probability ranges was achieved over two rounds of dis-
cussion. A post-meeting follow-up questionnaire con-
firmed agreement with all captured probability estimates. 
RESULTS: Structure validation was achieved by consen-
sus regarding the sequential management of SM. The pri-
mary decision nodes were identified as: empiric antibiotic
use, lumbar puncture (LP), antibiotics post LP, hospital
admission, and post-discharge physician visit. 
CONCLUSIONS: A single DAF can represent current clin-
ical management practices and outcomes for SM for pa-
tients of all ages. The primary drivers in the DAF were an-
tibiotic use and LP leading to the need for hospitalization.
Therapeutic agents to reduce the need for hospitalization
and procedures would significantly impact current man-
